FindTrial
Sign In

Pathological study of hepatic metabolic diseases

Copper restoration by liver Ceruloplasmin ablation ameliorates NAFLD through assembling of SCO1-AMPK-LKB1 complex

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048122
Enrollment
Unknown
Registered
2021-07-02
Start date
2021-05-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic diseases of the liver

Interventions

Case series:No

Sponsors

Shanghai No.6 People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who are suspected to be diagnosed as fatty liver by physical examination and imaging examination and are to be examined for liver biopsy 2. Age and gender are not limited

Exclusion criteria

Exclusion criteria: 1. Patients with alcoholic fatty liver disease; 2. Other causes of hepatic fatty degeneration were excluded; 3. Eliminate heavy drinking; 4. not combined with chronic liver disease.

Design outcomes

Primary

MeasureTime frame
secreted proteins Cp and FCN3;liver lipid metabolism;—

Contacts

Public ContactJunli Liu

Shanghai 6th People's Hospital

liujunli@sjtu.edu.cn+86 18321928502

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026